Oncolytics Biotech ONCY today announced a poster presentation
containing updated efficacy data from a Phase 2 study examining the use
of REOLYSIN® in combination with carboplatin and paclitaxel in patients with stage
IV non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumors (REO 016) was made at International
Association for the Study of Lung Cancer (IASLC). The conference is
being held from October 27th to 30th, 2013 in Sydney, Australia.
The poster presentation included new efficacy data that correlated a
number of molecular abnormalities with best response, progression free
survival (PFS) and one-year survival. Current data in these patients
demonstrates that 20 of 36 evaluable patients (56%) survived a year or
more. There were 13 patients with only EGFR mutations or
amplifications, of whom nine (69.2%) survived a year or longer. Four of
four (100%) patients with BRAF and EGFR amplification survived a year
or longer.
"This is the first time we have reported data correlating the presence
of specific biomarkers with efficacy, which covers both best response
and survival in patient tumours with a Ras-activated pathway," said Dr.
Brad Thompson, President and CEO of Oncolytics. "Although the study
examined a
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in